Roche subsidiary GenMark Diagnostics introduces the rebranded and improved cobas® eplex system

  • GenMark has rebranded its rapid syndromic molecular diagnostic solution under the Roche cobas brand, with upgraded features based on customer input across all aspects of the workflow process.

  • The system’s syndromic panels provide rapid, comprehensive diagnosis for a broad range of pathogens that can cause infections where diagnoses are not clear from symptoms alone.

  • Roche and GenMark are dedicated to providing world-class solutions for multiplex testing, with enhanced features that contribute to Roche’s commitment to helping diagnose infectious diseases and reduce antibiotic resistance.


SAN DIEGO, April 26, 2024 – (SIX: RO, ROG; OTCQX: RHHBY) GenMark, a member of the Roche Group, announced today that it has rebranded its ePlex® system as the cobas eplex system. The cobas eplex system launch under the globally recognized cobas brand highlights Roche’s commitment to continuous product improvement across the entire platform, from raw materials to manufacturing and quality control. 


We are pleased to offer the healthcare community a redesigned and enhanced cobas eplex system,” said Josh Lauer, Head of the Molecular Labs Customer Area at Roche Diagnostics Solutions. “These are syndromic panels, so patients can benefit from a rapid, comprehensive diagnosis for a broad range of pathogens that can cause infection with similar symptoms, for example, influenza, COVID-19 and RSV. This is especially important in patients who are at high risk, namely the elderly, very young and immunocompromised.


The cobas eplex system incorporates an updated design and features to improve usability, reliability and serviceability. Some of these features include on-board quality control tracking and monitoring, eSignature, onboard epidemiology reports, email alerts and customizable comments to aid in treatment. Similarly, GenMark implemented improvements to its cartridge manufacturing processes that will ensure both sufficient supply and validity improvements. 

The cobas eplex system tests for infectious diseases, specifically with test panels for respiratory infections and bloodstream infections, which can lead to sepsis, with panels in development for gastrointestinal infections, meningitis and encephalitis. 

The cobas eplex system integrates the entire process from order-to-report in order to better realize the patient and laboratory benefits of rapid, syndromic molecular diagnostics. The cobas eplex system will be unveiled at the 34th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), taking place April 27-30 in Barcelona, Spain. To learn more about what Roche will be presenting at this year’s Congress, please visit Roche at ECCMID 2024.


About the cobas eplex system


The cobas eplex system is a true sample-to-answer solution designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal* infections.

The cobas eplex system respiratory pathogen Panel 2 (RP2) is a multiplexed nucleic acid test for the qualitative detection of more than 20 common viral bacterial pathogens that can cause respiratory infections. The Roche RP2 test has not been Food and Drug Administration (FDA) cleared or approved. This test has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories.

The cobas eplex blood culture identification panels (BCID) are multiplexed nucleic acid tests for the qualitative detection of ~95% of the organisms that can cause bloodstream infections which can lead to sepsis. This is the broadest coverage of gram-positive, gram-negative, and fungal organisms and resistance genes.

* In development, not commercially available in the US.


About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. 

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. 

For more information, please visit

All trademarks used or mentioned in this release are protected by law.

For Further Information

Roche Diagnostics U.S. Media Relations

[email protected]


Krystina Monaco 


[email protected]